Clovis Oncology (NASDAQ:CLVS) Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction dated Monday, April 9th. The shares were sold at an average price of $60.02, for a total transaction of $270,090.00. Following the completion of the sale, the director now directly owns 7,618 shares of the company’s stock, valued at approximately $457,232.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Thorlef Spickschen also recently made the following trade(s):
- On Thursday, March 8th, Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock. The shares were sold at an average price of $61.47, for a total transaction of $276,615.00.
- On Thursday, February 22nd, Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock. The shares were sold at an average price of $60.00, for a total transaction of $270,000.00.
Shares of Clovis Oncology stock traded up $3.27 on Monday, reaching $58.79. 2,399,106 shares of the stock were exchanged, compared to its average volume of 1,276,313. Clovis Oncology has a one year low of $45.42 and a one year high of $99.45. The company has a current ratio of 7.69, a quick ratio of 7.35 and a debt-to-equity ratio of 0.77. The company has a market cap of $2,807.82, a PE ratio of -11.48 and a beta of 0.93.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.29) by $0.25. The company had revenue of $17.04 million during the quarter, compared to the consensus estimate of $19.42 million. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The firm’s quarterly revenue was up 21746.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.83) EPS. research analysts forecast that Clovis Oncology will post -4.85 earnings per share for the current year.
A number of analysts have issued reports on the stock. Bank of America reissued a “buy” rating and issued a $55.52 price objective (down previously from $90.00) on shares of Clovis Oncology in a report on Monday. SunTrust Banks boosted their price objective on shares of Clovis Oncology to $90.00 and gave the company a “buy” rating in a report on Monday. Cann reissued a “hold” rating on shares of Clovis Oncology in a report on Sunday. Credit Suisse Group set a $86.00 price objective on shares of Clovis Oncology and gave the company a “buy” rating in a report on Friday. Finally, BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, March 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Clovis Oncology has an average rating of “Buy” and a consensus price target of $87.60.
A number of large investors have recently modified their holdings of the stock. Xact Kapitalforvaltning AB bought a new position in Clovis Oncology in the 4th quarter valued at approximately $328,000. Delek Group Ltd. bought a new position in Clovis Oncology in the 4th quarter valued at approximately $2,852,000. MetLife Investment Advisors LLC bought a new position in Clovis Oncology in the 4th quarter valued at approximately $1,374,000. Endurant Capital Management LP lifted its stake in Clovis Oncology by 19.2% in the 4th quarter. Endurant Capital Management LP now owns 67,650 shares of the biopharmaceutical company’s stock valued at $4,600,000 after purchasing an additional 10,900 shares during the last quarter. Finally, Palo Alto Investors LLC lifted its stake in Clovis Oncology by 2.2% in the 4th quarter. Palo Alto Investors LLC now owns 3,402,781 shares of the biopharmaceutical company’s stock valued at $231,389,000 after purchasing an additional 73,200 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/clovis-oncology-clvs-director-thorlef-spickschen-sells-4500-shares.html.
About Clovis Oncology
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.